Skip to main content
padlock icon - secure page this page is secure

Open Access Search for super early biomarker of multiple sclerosis using mass spectrometry imaging

Download Article:
 Download
(PDF 264.3 kb)
 
Multiple sclerosis (MS) is a disease that affects the central nervous system. It is a lifelong condition with no cure, but it can be managed with treatments and specialists. For example, treatment can focus on accelerating recovery from attacks, slowing disease progression and managing symptoms. Symptoms caused by MS include fatigue, visual problems, muscle spasms and stiffness, mobility problems, neuropathic pain and problems with thinking, learning and memory, among others. Professor Masaya Ikegawa is a researcher based in the Department of Medical Life Systems at Doshisha University, Japan. His latest research project ('Search for super early biomarker of multiple sclerosis using mass spectrometry imaging') involves identifying biomarkers and therapeutic targets of MS through imaging mass spectrometry. His research also encompasses a broader spectrum of intractable diseases, which are those that have mostly arisen through unidentifiable causes and lack established or curable treatments, including Alzheimer's disease, diabetic neuropathy and cancer, among others.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ALZHEIMER'S DISEASE; AUTOIMMUNE DISEASE; CANCER; CARDIOVASCULAR DISEASES; DIABETES; GENOMIC APPROACHES; INTRACTABLE DISEASES; METABOLOMIC APPROACHES; MULTIPLE SCLEROSIS-RELATED DISORDERS; NEUROMYELITIS OPTICA; PROTEOMIC APPROACHES

Document Type: Research Article

Publication date: November 1, 2019

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more